Literature DB >> 21616999

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Roland M du Bois1, Derek Weycker, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Alex Kartashov, Lisa Lancaster, Paul W Noble, Ganesh Raghu, Steven A Sahn, Javier Szwarcberg, Michiel Thomeer, Dominique Valeyre, Talmadge E King.   

Abstract

RATIONALE: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have been described; however, there is a need for a practical and accurate method of quantifying the prognosis of individual patients.
OBJECTIVES: Develop a practical mortality risk scoring system for patients with idiopathic pulmonary fibrosis.
METHODS: We used a Cox proportional hazards model and data from two clinical trials (n = 1,099) to identify independent predictors of 1-year mortality among patients with idiopathic pulmonary fibrosis. From the comprehensive model, an abbreviated clinical model comprised of only those predictors that are readily and reliably ascertained by clinicians was derived. Beta coefficients for each predictor were then used to develop a practical mortality risk scoring system.
MEASUREMENTS AND MAIN RESULTS: Independent predictors of mortality included age, respiratory hospitalization, percent predicted FVC, 24-week change in FVC, percent predicted carbon monoxide diffusing capacity, 24-week change in percent predicted carbon monoxide diffusing capacity, and 24-week change in health-related quality of life. An abbreviated clinical model comprising only four predictors (age, respiratory hospitalization, percent predicted FVC, and 24-wk change in FVC), and the corresponding risk scoring system produced estimates of 1-year mortality risk consistent with observed data (9.9% vs. 9.7%; C statistic = 0.75; 95% confidence interval, 0.71–0.79).
CONCLUSIONS: The prognosis for patients with idiopathic pulmonary fibrosis may be accurately determined using four readily ascertainable predictors. Our simplified scoring system may be a valuable tool for determining prognosis and guiding clinical management. Additional research is needed to validate the applicability and accuracy of the scoring system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616999     DOI: 10.1164/rccm.201011-1790OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  106 in total

1.  Plasma proteins for risk prediction in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-06-15       Impact factor: 21.405

Review 2.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

3.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

Review 4.  Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society.

Authors:  Coenraad F N Koegelenberg; Gillian M Ainslie; Keertan Dheda; Brian W Allwood; Michelle L Wong; Umesh G Lalloo; Mohamed S Abdool-Gaffar; Hoosain Khalfey; Elvis M Irusen
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

5.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

7.  Patient-reported outcomes in idiopathic pulmonary fibrosis research.

Authors:  Jeffrey J Swigris; Diane Fairclough
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

8.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2017-02-23

9.  Relationship between survival and age in patients with idiopathic pulmonary fibrosis.

Authors:  So-My Koo; Soo-Taek Uh; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Moo Suk Park; Young Hwangbo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 10.  The diagnosis and treatment of idiopathic pulmonary fibrosis.

Authors:  Jürgen Behr
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.